Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis

BACKGROUND: Newly approved immunotherapeutic agents, like CTLA-4 inhibitors and antibodies against PD-1, are a promising therapeutic option in cancer therapy. CASE PRESENTATION: A 74-year-old man, with a history of advanced stage melanoma and treatment with ipilimumab, pembrolizumab and nivolumab, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Thomas-Michael, Klenner, Friederike, Brettner, Franz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter Open 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769916/
https://www.ncbi.nlm.nih.gov/pubmed/29967877
http://dx.doi.org/10.1515/jccm-2017-0013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769916/
https://www.ncbi.nlm.nih.gov/pubmed/29967877
http://dx.doi.org/10.1515/jccm-2017-0013

Ejemplares similares